이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Vita Life Sciences 대차 대조표 상태

재무 상태 기준 확인 6/6

Vita Life Sciences 의 총 주주 지분은 A$43.3M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$59.8M 및 A$16.5M 입니다. Vita Life Sciences 의 EBIT는 A$11.9M 이며 이자보상배율은 -23.8 입니다. A$24.6M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	-13.1x
현금	AU$27.75m
주식	AU$48.70m
총 부채	AU$19.25m
총 자산	AU$67.95m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: VLS 의 단기 자산 ( A$48.3M )이 단기 부채( A$16.2M ).

장기 부채: VLS 의 단기 자산( A$48.3M )이 장기 부채( A$260.0K ).

부채 대 자본 내역 및 분석

부채 수준: VLS 부채가 없습니다.

부채 감소: VLS 는) 부채 대 자기자본 비율이 9.3% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: VLS 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: VLS 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Vita Life Sciences 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기